What “success rate” usually means for Cosentyx
Searchers typically mean one of two things when they ask how Cosentyx performs versus other biologics: how many patients achieve a major clinical improvement (often PASI-75/PASI-90 in psoriasis, ACR/NRS/ASAS in arthritis, or similar composite endpoints), or how durable those responses are over time. The exact comparison depends on the disease (psoriasis vs psoriatic arthritis vs ankylosing spondylitis) and the trial endpoint used. The provided information does not include Cosentyx’s specific response rates or the competing biologics’ rates, so a head-to-head success-rate comparison can’t be determined from the available data.
How to compare Cosentyx with other biologics (apples-to-apples)
To compare “success rates” fairly across biologics, you generally need:
- The same indication (e.g., plaque psoriasis vs psoriatic arthritis).
- The same study design and timeframe (induction vs maintenance period).
- The same endpoint definition (e.g., PASI-75 at week 16 vs PASI-90 at week 52).
- Comparable patient baseline severity and prior biologic exposure.
Without those details and the underlying numbers, any claim about which drug is “better” would be unsupported.
If you tell me the indication, I can narrow the comparison
If you share which condition you mean, I can structure the comparison in the way trials report it:
- Plaque psoriasis (skin-focused response endpoints)
- Psoriatic arthritis (joint/function composite endpoints)
- Ankylosing spondylitis / axial spondyloarthritis (spine and inflammatory activity endpoints)
Which competing biologics are usually compared to Cosentyx?
Common comparisons depend on the disease and the mechanism being targeted (for example, IL-17 inhibitors versus TNF inhibitors versus IL-12/23, IL-23, or IL-23p19 inhibitors). But the specific “success rate” matchup still requires the actual response rates from the relevant trials or an accepted indirect-treatment comparison source—neither is included in the provided information.
What I need to answer your question with real numbers
To compare Cosentyx’s success rate against alternative biologics accurately, send either:
- The specific biologics you want compared (e.g., secukinumab vs adalimumab vs ustekinumab vs ustekinumab vs risankizumab, etc.), and the disease; or
- The trial endpoints/timepoints you care about (e.g., “PASI-90 at week 16 for moderate-to-severe plaque psoriasis”).
Then I can synthesize the reported response rates and highlight where one therapy tends to outperform another and where results are similar.
Sources
No sources were provided with the information needed to compare Cosentyx’s success rate to alternative biologics.